Dextech Medical AB engages in the development of drug candidates with application in urological oncology, primarily prostate cancer. The company’s lead candidate, OsteoDex that has completed a phase IIb clinical trial for the treatment of bone metastases in castration-resistant prostate cancer, as well as in preclinical stage to treat breast and lung cancer, as well as multiple myeloma. The company is also developing SomaDex, a medication candidate that is based on an endogenous hormone, somatostatin, to treat acromegaly, neuroendocrine tumors, and palliative treatment for advanced prostate cancer; and PSMA-binding conjugates for the target-specific treatment of mCRPC that overexpresses prostate specific membrane antigen (PSMA). In addition, the company offers GuaDex (formarly CatDex), a technology platform and a charge-modified dextran molecule with tumor-toxic properties used for medication development. Dextech Medical AB was incorporated in 2004 and is based in Uppsala, Sweden.
Metrics to compare | DEXTECH | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDEXTECHPeersSector | |
|---|---|---|---|---|
P/E Ratio | −42.5x | −3.0x | −0.5x | |
PEG Ratio | 24.79 | −0.08 | 0.00 | |
Price/Book | 8.5x | 9.8x | 2.6x | |
Price / LTM Sales | 60.8x | 16.5x | 3.3x | |
Upside (Analyst Target) | - | 113.4% | 47.0% | |
Fair Value Upside | Unlock | −2.6% | 5.9% | Unlock |